Via Oncology Publications
Mason C et al. Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non–Small Cell Lung Cancer Treatment Setting.
[Manuscript] J Clin Pathways 2017 4(1):49-54
Page R et al. Expanding indications of existing drugs and associated costs under risk reimbursement models.
[Abstract] J Clin Oncol 35, 2017 (suppl; abstr e18306)
Ellis PG et al. Using clinical pathways to understand biomarker testing patterns.
[Abstract] J Clin Oncol 35, 2017 (suppl; abstr e18189)
Ellis PG, O’Neil BH, Earle MF, et al. Clinical pathways: management of quality and cost in oncology networks in the metastatic colorectal cancer setting.
[Article] J Oncol Pract. 2017 Apr 5.
Ellis PG et al. Impact of varying approaches used to compare costs between drug regimens.
[Abstract] J Clin Oncol 34, 2016 (suppl; abstr e18262)
Friedland D et al. Evaluating the impact of Via Pathways (VP) on the adoption of changing treatment paradigms in metastatic hormone-sensitive prostate cancer (mHSPC).
[Abstract] J Clin Oncol 34, 2016 (suppl; abstr e16510)
McCutcheon S et al. Frequency of efficacy, toxicity and cost as the deciding factor when determining clinical pathways
[Abstract] J Clin Oncol 34, 2016 (suppl; abstr e18169)
Ellis PG et al. Pathways Clinical Decision Support for Appropriate Use of Key Biomarkers.
[Article] JOP May 24, 2016 JOPR010546
Ellis PG, Weese JL. Clinical pathways as a platform to support clinical research.
[Abstract] [Poster] Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, 2016 (ABSTR 2594)
Heron DE et al. The standardization of skin cancer treatment recommendations through the analysis of clinical pathways data and an evidence-based, physician-driven committee process.
[Abstract] [Poster] J Clin Oncol 34, 2016 (suppl 7S; abstr 147)
Ellis PG et al. Incorporation of a patient question prompt list into a pancreatic cancer pathway.
[Abstract] J Clin Oncol 33 (suppl 29S; abstr 20) 2015
Via Network Publications
Rodríguez-Lopéz JL, Ling DC, Heron DE, Beriwal S. Lag Time Between Evidence and Guidelines: Can Clinical Pathways Bridge the Gap?
[Article] JOP. December 2018:JOP.18.00430
Cost and survival analysis before and after implementation of Dana-Farber Clinical Pathways for Patients with Stage IV Non-Small Cell Lung Cancer.
[Article] J Oncol Pract. 2017 Apr;13(4):e346-e352
Gebhardt BJ et al. Peer review process for implementation of clinical pathways (CP): Does it improve compliance?
[Abstract] Pract Radiat Oncol. 2017 Jan 19. pii: S1879-8500(17)30006-1. doi: 10.1016/j.prro.2017.01.006.
Insights From Building a New National Cancer Institute Community Oncology Research Program Site
[Article] J Clin Oncol 34, 2016 (suppl; abstr 6613)
Shamah CJ, Saphner TJ. Effect on clinical trial participation by integration of a clinical pathway program into an electronic health record (EHR).
[Abstract] [Poster] J Clin Oncol 34, 2016 (suppl 7S; abstr 167)
Shamah CJ et al. Integration of a clinical pathways software into an EHR in a large, multisite, hospital-affiliated community oncology setting.
[Abstract] [Poster] J Clin Oncol 34, 2016 (suppl 7S; abstr 129)
Gebhardt BJ et al. Impact of dynamic changes to a bone metastases pathway in a large, integrated, National Cancer Institute-designated comprehensive cancer center network.
[Abstract] Pract Radiat Oncol. 2015 Nov-Dec;5(6):398-405
Rajagopalan MS et al. Changing practice patterns for breast cancer radiation therapy with clinical pathways: An analysis of hypofractionation in a large, integrated cancer center network.
[Abstract] Pract Radiat Oncol. 2015 Mar-Apr;5(2):63-9
Newcomer LN et al. Changing physician incentives for affordable, quality cancer care: results of an episode payment model.
[Abstract] J Oncol Pract. 2014 Sep;10(5):322-6